[96a5a0]: / output / allTrials / identified / NCT00593060_identified.json

Download this file

490 lines (490 with data), 20.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
{
"info": {
"nct_id": "NCT00593060",
"official_title": "A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer",
"inclusion_criteria": "* Previously treated metastatic colorectal adenocarcinoma, histologically proven. Subjects must have previously received and had evidence of progression on cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin, or demonstrated intolerance to those agents (except cetuximab).\n* Measurable disease by RECIST criteria\n* ECOG Performance Status 0 or 1.\n* Male or female, 18 years of age or older.\n* Life expectancy greater than or equal to 12 weeks.\n* At least 2 weeks have elapsed between previous anti-cancer therapy AND resolution of any skin rash related to prior treatment with an epidermal growth factor receptor inhibitor.\n* Lab values within ranges as outlined in protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Diagnosis of second malignancy within the last 3 years, except for adequately treated basal cell carcinoma or squamous cell skin cancer.\n* Ongoing cardiac dysrhythmias of NCI CTCAE grade >/=2, atrial fibrillation, QTc prolongation to >450msec for males and >470 msec for females.\n* Known immunodeficiency disorders or active infections requiring treatment\n* Pregnancy or breastfeeding\n* Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease\n* Prior radiation therapy or major surgery within 2 weeks of study entry\n* Prior radiation therapy to > 25% of the bone marrow\n* Treatment with other experimental or alternative therapies during the course of the trial\n* History of hypersensitivity to polysorbate or cetuximab",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Previously treated metastatic colorectal adenocarcinoma, histologically proven. Subjects must have previously received and had evidence of progression on cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin, or demonstrated intolerance to those agents (except cetuximab).",
"criterions": [
{
"exact_snippets": "Previously treated metastatic colorectal adenocarcinoma, histologically proven.",
"criterion": "metastatic colorectal adenocarcinoma",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": "previously treated"
},
{
"requirement_type": "confirmation",
"expected_value": "histologically proven"
}
]
},
{
"exact_snippets": "Subjects must have previously received and had evidence of progression on cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin, or demonstrated intolerance to those agents (except cetuximab).",
"criterion": "treatment with cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin",
"requirements": [
{
"requirement_type": "progression evidence",
"expected_value": true
},
{
"requirement_type": "intolerance",
"expected_value": true
}
]
}
]
},
{
"line": "* Measurable disease by RECIST criteria",
"criterions": [
{
"exact_snippets": "Measurable disease by RECIST criteria",
"criterion": "disease",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": "RECIST criteria"
}
]
}
]
},
{
"line": "* ECOG Performance Status 0 or 1.",
"criterions": [
{
"exact_snippets": "ECOG Performance Status 0 or 1",
"criterion": "ECOG Performance Status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Male or female, 18 years of age or older.",
"criterions": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "18 years of age or older",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Life expectancy greater than or equal to 12 weeks.",
"criterions": [
{
"exact_snippets": "Life expectancy greater than or equal to 12 weeks.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* At least 2 weeks have elapsed between previous anti-cancer therapy AND resolution of any skin rash related to prior treatment with an epidermal growth factor receptor inhibitor.",
"criterions": [
{
"exact_snippets": "At least 2 weeks have elapsed between previous anti-cancer therapy",
"criterion": "time since previous anti-cancer therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "resolution of any skin rash related to prior treatment with an epidermal growth factor receptor inhibitor",
"criterion": "skin rash related to prior treatment with an epidermal growth factor receptor inhibitor",
"requirements": [
{
"requirement_type": "resolution",
"expected_value": true
}
]
}
]
},
{
"line": "* Lab values within ranges as outlined in protocol",
"criterions": [
{
"exact_snippets": "Lab values within ranges",
"criterion": "lab values",
"requirements": [
{
"requirement_type": "range",
"expected_value": "as outlined in protocol"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Diagnosis of second malignancy within the last 3 years, except for adequately treated basal cell carcinoma or squamous cell skin cancer.",
"criterions": [
{
"exact_snippets": "Diagnosis of second malignancy within the last 3 years",
"criterion": "second malignancy",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "except for adequately treated basal cell carcinoma or squamous cell skin cancer",
"criterion": "basal cell carcinoma or squamous cell skin cancer",
"requirements": [
{
"requirement_type": "treatment adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Ongoing cardiac dysrhythmias of NCI CTCAE grade >/=2, atrial fibrillation, QTc prolongation to >450msec for males and >470 msec for females.",
"criterions": [
{
"exact_snippets": "Ongoing cardiac dysrhythmias of NCI CTCAE grade >/=2",
"criterion": "cardiac dysrhythmias",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "NCI CTCAE grade"
}
}
]
},
{
"exact_snippets": "atrial fibrillation",
"criterion": "atrial fibrillation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "QTc prolongation to >450msec for males",
"criterion": "QTc prolongation",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 450,
"unit": "msec"
}
}
]
},
{
"exact_snippets": "QTc prolongation to ... >470 msec for females",
"criterion": "QTc prolongation",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 470,
"unit": "msec"
}
}
]
}
]
},
{
"line": "* Known immunodeficiency disorders or active infections requiring treatment",
"criterions": [
{
"exact_snippets": "Known immunodeficiency disorders",
"criterion": "immunodeficiency disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active infections requiring treatment",
"criterion": "active infections",
"requirements": [
{
"requirement_type": "treatment requirement",
"expected_value": true
}
]
}
]
},
{
"line": "* Pregnancy or breastfeeding",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease",
"criterions": [
{
"exact_snippets": "Brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "spinal cord compression",
"criterion": "spinal cord compression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "carcinomatous meningitis",
"criterion": "carcinomatous meningitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "leptomeningeal disease",
"criterion": "leptomeningeal disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior radiation therapy or major surgery within 2 weeks of study entry",
"criterions": [
{
"exact_snippets": "Prior radiation therapy",
"criterion": "prior radiation therapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "major surgery within 2 weeks of study entry",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Prior radiation therapy to > 25% of the bone marrow",
"criterions": [
{
"exact_snippets": "Prior radiation therapy to > 25% of the bone marrow",
"criterion": "radiation therapy to bone marrow",
"requirements": [
{
"requirement_type": "extent",
"expected_value": {
"operator": ">",
"value": 25,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Treatment with other experimental or alternative therapies during the course of the trial",
"criterions": [
{
"exact_snippets": "Treatment with other experimental or alternative therapies",
"criterion": "treatment with experimental or alternative therapies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* History of hypersensitivity to polysorbate or cetuximab",
"criterions": [
{
"exact_snippets": "History of hypersensitivity to polysorbate",
"criterion": "hypersensitivity to polysorbate",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of hypersensitivity to ... cetuximab",
"criterion": "hypersensitivity to cetuximab",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}